[The pharmacology of endothelin and its antagonist bosentan].
Endothelin is one of the most potent vasoconstrictors known, but it also plays a role in inflammation, fibrosis and cellular hypertrophy. Endothelin is a key pathogenic factor in congestive heart failure, essential hypertension and pulmonary hypertension. Bosentan is a specific mixed antagonist of endothelin receptors. Preclinical and clinical data suggest that bosentan might become a new approach for the chronic treatment of these cadiovascular and pulmonary diseases.
Clozel
M
M
Actelion Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
Roux
S
S
D000818:Animals; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000494:pharmacology / Q000502:physiology*; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D013449:Sulfonamides; D000077300:Bosentan